Litcius/Paper detail

Angiotensin-converting-enzyme inhibitor–induced angioedema

Danica Quickfall, Baruch D. Jakubovic, Jonathan S. Zipursky

2021Canadian Medical Association Journal10 citationsDOIOpen Access PDF

Abstract

Angiotensin-converting-enzyme (ACE) inhibitors are responsible for 20%–40% of emergency department visits for angioedema.[1][1] The incidence of ACE inhibitor–induced angioedema is about 0.1%–0.7% in the first 5 years of treatment; symptoms occur within the first month in 10% of cases.[1][1]

Topics & Concepts

AngioedemaAngiotensin-converting enzymeACE inhibitorMedicineIncidence (geometry)Emergency departmentEnzyme inhibitorEnzymeInternal medicinePharmacologyDermatologyChemistryBiochemistryBlood pressurePhysicsPsychiatryOpticsCoagulation, Bradykinin, Polyphosphates, and AngioedemaBlood Coagulation and Thrombosis MechanismsVitamin K Research Studies